Most Recent
A Federal Court judge skipped vital witness testimony when he ruled Reckitt Benckiser misled consumers about the effectiveness of its Nurofen painkiller, the pharmaceutical company told the Full Federal Court Monday.
Two patent infringement lawsuits have been launched over attempts to sell generic versions of breakthrough cancer drug Velcade in Australia, after a US court last year struck down attempts to invalidate a patent for the drug.
A Sydney pharmacist who was stripped of his registration after selling counterfeit Viagra has lost an application to have his licence reinstated.
Ethicon told the Full Federal Court on Monday that the judge overseeing the marathon class action against it over allegedly defective vaginal mesh devices got it wrong when she reset the dates for inclusion in the class.
Pharmaceutical and life sciences giant Bayer is facing a potential class action in Australia over its birth control device Essure, which can allegedly cause nickel poisoning and other severe complications.
Consumer goods giant Reckitt Benckiser has been ordered by the Federal Court to remove all in-store advertising for its Strepfen throat lozenges after a successful interlocutory application by rival iNova Pharmaceuticals.
Ophthalmic diagnostic device manufacture ObjectiVision can't file amended claims for damages following a trial in a copyright and contract case against the University of Sydney, with a judge saying the school would be "severely prejudiced" if the new claims were allowed.
Ophthalmic diagnostic device maker ObjectiVision's amended claims for damages, filed after a 25-day patent hearing, are "outlandish" and "unfair," the University of Sydney has told the Federal Court.
The final day of trial in the ACCC's case over muscle gel Voltaren wrapped up Wednesday with a barrister for GlaxoSmithKline slamming as 'onerous' a compliance regime proposed by the consumer watchdog and blasting an injunction as unnecessary for a problem the pharmaceutical giant 'inherited' from Novartis.
The first day of a liability hearing in a consumer case over GlaxoSmithKline's marketing for its popular Voltaren products has seen an ACCC witness deflect accusations the regulator was vague about its misleading packaging concerns, placing the blame squarely on the pharmaceutical giant.